The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study Comparative Study
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
Recurrent cervical cancer is a life-threatening disease, with limited treatment options available when disease progression occurs after first-line combination therapy. ⋯ In patients with recurrent cervical cancer, second- or third-line treatment with tisotumab vedotin resulted in significantly greater efficacy than chemotherapy. (Funded by Genmab and Seagen [acquired by Pfizer]; innovaTV 301 ClinicalTrials.gov number, NCT04697628.).
-
Editorial Review
New Therapies for Type 1 and Type 2 Hereditary Angioedema.